182 related articles for article (PubMed ID: 38333210)
21. Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses.
Odunsi K; Qian F; Lugade AA; Yu H; Geller MA; Fling SP; Kaiser JC; Lacroix AM; D'Amico L; Ramchurren N; Morishima C; Disis ML; Dennis L; Danaher P; Warren S; Nguyen VA; Ravi S; Tsuji T; Rosario S; Zha W; Hutson A; Liu S; Lele S; Zsiros E; McGray AJR; Chiello J; Koya R; Chodon T; Morrison CD; Putluri V; Putluri N; Mager DE; Gunawan R; Cheever MA; Battaglia S; Matsuzaki J
Sci Transl Med; 2022 Mar; 14(636):eabg8402. PubMed ID: 35294258
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis, and biological evaluation of 1,2,5-oxadiazole-3-carboximidamide derivatives as novel indoleamine-2,3-dioxygenase 1 inhibitors.
Song X; Sun P; Wang J; Guo W; Wang Y; Meng LH; Liu H
Eur J Med Chem; 2020 Mar; 189():112059. PubMed ID: 31981851
[TBL] [Abstract][Full Text] [Related]
23. Trial watch: IDO inhibitors in cancer therapy.
Le Naour J; Galluzzi L; Zitvogel L; Kroemer G; Vacchelli E
Oncoimmunology; 2020 Jun; 9(1):1777625. PubMed ID: 32934882
[TBL] [Abstract][Full Text] [Related]
24. The signaling function of IDO1 incites the malignant progression of mouse B16 melanoma.
Orecchini E; Belladonna ML; Pallotta MT; Volpi C; Zizi L; Panfili E; Gargaro M; Fallarino F; Rossini S; Suvieri C; Macchiarulo A; Bicciato S; Mondanelli G; Orabona C
Oncoimmunology; 2023; 12(1):2170095. PubMed ID: 36733497
[TBL] [Abstract][Full Text] [Related]
25. Design, Synthesis and Biological Evaluation of Novel 1,2,5-Oxadiazol-3- Carboximidamide Derivatives as Indoleamine 2, 3-Dioxygenase 1 (IDO1) Inhibitors.
Xia Z; Nan Y; Liu C; Lin G; Gu K; Chen C; Zhao W; Ju D; Dong X
Anticancer Agents Med Chem; 2020; 20(13):1592-1603. PubMed ID: 32496990
[TBL] [Abstract][Full Text] [Related]
26. Indoleamine dioxygenase and tryptophan dioxygenase activities are regulated through GAPDH- and Hsp90-dependent control of their heme levels.
Biswas P; Dai Y; Stuehr DJ
Free Radic Biol Med; 2022 Feb; 180():179-190. PubMed ID: 35051612
[TBL] [Abstract][Full Text] [Related]
27. Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond.
Muller AJ; Manfredi MG; Zakharia Y; Prendergast GC
Semin Immunopathol; 2019 Jan; 41(1):41-48. PubMed ID: 30203227
[TBL] [Abstract][Full Text] [Related]
28. A patent review of IDO1 inhibitors for cancer.
Cheong JE; Ekkati A; Sun L
Expert Opin Ther Pat; 2018 Apr; 28(4):317-330. PubMed ID: 29473428
[TBL] [Abstract][Full Text] [Related]
29. Forced IDO1 expression in dendritic cells restores immunoregulatory signalling in autoimmune diabetes.
Pallotta MT; Orabona C; Bianchi R; Vacca C; Fallarino F; Belladonna ML; Volpi C; Mondanelli G; Gargaro M; Allegrucci M; Talesa VN; Puccetti P; Grohmann U
J Cell Mol Med; 2014 Oct; 18(10):2082-91. PubMed ID: 25215657
[TBL] [Abstract][Full Text] [Related]
30. Inhibition Mechanisms of Indoleamine 2,3-Dioxygenase 1 (IDO1).
Röhrig UF; Reynaud A; Majjigapu SR; Vogel P; Pojer F; Zoete V
J Med Chem; 2019 Oct; 62(19):8784-8795. PubMed ID: 31525930
[TBL] [Abstract][Full Text] [Related]
31. Indoleamine 2,3-Dioxygenase 1: A Promising Therapeutic Target in Malignant Tumor.
Song X; Si Q; Qi R; Liu W; Li M; Guo M; Wei L; Yao Z
Front Immunol; 2021; 12():800630. PubMed ID: 35003126
[TBL] [Abstract][Full Text] [Related]
32. Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy.
Gomes B; Driessens G; Bartlett D; Cai D; Cauwenberghs S; Crosignani S; Dalvie D; Denies S; Dillon CP; Fantin VR; Guo J; Letellier MC; Li W; Maegley K; Marillier R; Miller N; Pirson R; Rabolli V; Ray C; Streiner N; Torti VR; Tsaparikos K; Van den Eynde BJ; Wythes M; Yao LC; Zheng X; Tumang J; Kraus M
Mol Cancer Ther; 2018 Dec; 17(12):2530-2542. PubMed ID: 30232146
[TBL] [Abstract][Full Text] [Related]
33. Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma.
Gibney GT; Hamid O; Lutzky J; Olszanski AJ; Mitchell TC; Gajewski TF; Chmielowski B; Hanks BA; Zhao Y; Newton RC; Maleski J; Leopold L; Weber JS
J Immunother Cancer; 2019 Mar; 7(1):80. PubMed ID: 30894212
[TBL] [Abstract][Full Text] [Related]
34. Discovery of novel IDO1 inhibitors targeting the protein's apo form through scaffold hopping from holo-IDO1 inhibitor.
Wu Y; Duan Q; Zou Y; Zhu Q; Xu Y
Bioorg Med Chem Lett; 2021 Nov; 52():128373. PubMed ID: 34560264
[TBL] [Abstract][Full Text] [Related]
35. Targeting immunometabolism mediated by the IDO1 Pathway: A new mechanism of immune resistance in endometrial cancer.
Passarelli A; Pisano C; Cecere SC; Di Napoli M; Rossetti S; Tambaro R; Ventriglia J; Gherardi F; Iannacone E; Venanzio SS; Fiore F; Bartoletti M; Scognamiglio G; Califano D; Pignata S
Front Immunol; 2022; 13():953115. PubMed ID: 36119020
[TBL] [Abstract][Full Text] [Related]
36. Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer.
Prendergast GC; Malachowski WJ; Mondal A; Scherle P; Muller AJ
Int Rev Cell Mol Biol; 2018; 336():175-203. PubMed ID: 29413890
[TBL] [Abstract][Full Text] [Related]
37. Role of indoleamine 2,3-dioxygenase in health and disease.
Yeung AW; Terentis AC; King NJ; Thomas SR
Clin Sci (Lond); 2015 Oct; 129(7):601-72. PubMed ID: 26186743
[TBL] [Abstract][Full Text] [Related]
38. Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I/II ECHO-207/KEYNOTE-723 Study.
Powderly JD; Klempner SJ; Naing A; Bendell J; Garrido-Laguna I; Catenacci DVT; Taylor MH; Lee JJ; Zheng F; Zhou F; Gong X; Gowda H; Beatty GL
Oncologist; 2022 Nov; 27(11):905-e848. PubMed ID: 36156099
[TBL] [Abstract][Full Text] [Related]
39. The immunomodulatory role of IDO1-Kynurenine-NAD
Anu RI; Shiu KK; Khan KH
Front Oncol; 2023; 13():1142838. PubMed ID: 37456260
[TBL] [Abstract][Full Text] [Related]
40. A peripheral blood mononuclear cell-based in vitro model: A tool to explore indoleamine 2, 3-dioxygenase-1 (IDO1).
Gonçalves M; Furgiuele A; Rasini E; Legnaro M; Ferrari M; Luini A; Rodrigues-Santos P; Caramelo F; Marino F; Pereira FC; Cosentino M
Eur J Pharmacol; 2024 Apr; 968():176420. PubMed ID: 38367683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
